Corbus Pharmaceuticals Holdings (CRBP) Change in Accured Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at $4.9 million for Q3 2025.

• In Q3 2025, Change in Accured Expenses rose 248.02% year-over-year to $4.9 million; the TTM figure through Sep 2025 stood at $5.4 million (up 1507.29% YoY), while the FY2024 annual figure was -$5.6 million, down 211.53% from the prior year.
• Change in Accured Expenses for Q3 2025 stood at $4.9 million, up from $1.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.9 million in Q3 2025, with the low at -$4.6 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$49050.0 (2023), against an average of -$496804.2.
• The sharpest annual moves came in 2021 and 2024: Change in Accured Expenses sank 484.0% in 2021, then jumped 2322.22% in 2024.
• Corbus Pharmaceuticals Holdings' Change in Accured Expenses stood at -$3.5 million in 2021, then soared by 133.06% to $1.2 million in 2022, then surged by 198.98% to $3.5 million in 2023, then sank by 150.03% to -$1.7 million in 2024, then surged by 382.44% to $4.9 million in 2025.
• Business Quant data shows CRBP's Change in Accured Expenses at $4.9 million in Q3 2025, $1.7 million in Q2 2025, and $476000.0 in Q1 2025.